Letters |

Radiation Therapy Modalities for Prostate Cancer

Bruce L. Jacobs, MD, MPH; Yun Zhang, PhD; Brent K. Hollenbeck, MD, MS
JAMA. 2012;308(5):450. doi:10.1001/jama.2012.8108.
Text Size: A A A
Published online


To the Editor: In the absence of randomized clinical trials, comparative effectiveness research plays a critical role in evaluating new technologies. However, because these studies invariably rely on observational data, the devil is in the details.

The recent study by Dr Sheets and colleagues1 related to the comparative effectiveness of radiation therapy modalities for prostate cancer highlights this concern in 2 ways. The first relates to treatment assignment, or in this case, the type of radiation. The authors broadly assigned patients to conformal therapy (the predecessor to intensity-modulated radiation therapy [IMRT] and proton beam), invariably including patients with conventional, stereotactic, and neutron beam therapies. It is established in randomized trials that conventional therapy is associated with greater morbidity and is less effective than conformal radiation for prostate cancer.2 In fact, the use of conventional therapy during the period of study was significant.3 Given the relatively small effect size described in the article, such misclassification might explain the observed differences. An alternative approach would have been to incorporate treatment planning codes specific to conformal therapy to obtain a more homogenous comparison group.3,4


Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview




August 1, 2012
Nancy P. Mendenhall, MD; Steven Schild, MD; Jerry Slater, MD
JAMA. 2012;308(5):450. doi:10.1001/jama.2012.8112.
August 1, 2012
Curtiland Deville, MD; Edgar Ben-Josef, MD; Neha Vapiwala, MD
JAMA. 2012;308(5):450. doi:10.1001/jama.2012.8110.
August 1, 2012
Anne-Marie Meyer, PhD; Paul A. Godley, MD, PhD; Ronald Chen, MD, MPH
JAMA. 2012;308(5):450. doi:10.1001/jama.2012.8114.
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.